17006-60-9

Upstream product

• 17006-59-6 3β-Hydroxy-17-ethylendioxy-3α-ethinyl-5α-androstan 
• 846-46-8 androstanedione 
• 4301-14-8 acetylenemagnesium bromide 
• 521-18-6 Stanolone 
• 521-18-6 stanolone 
• 10148-98-8 (3S,5S,8R,9S,10S,13S,14S,17S)-3-ethynyl-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol 

Downstream Products

• 2089238-18-4 3α-ethynyl-3β-hydroxyandrostan-17-one oxime 

Relevant academic research and scientific papers

METHODS AND MEDICAL USES

There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3α-ethynyl-3β-hydroxy-5α-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY

The present invention provides the steroidal compound3?-ethynyl-3?- hydroxyandrostan-17-one oxime,or a pharmaceutically acceptable saltthereof,for usein treatment ofhepaticencephalopathy.

NEW STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM, AND METHODS FOR THEIR PRODUCTION

Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.